Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%

Vivos Therapeutics, Inc.

2024-Q2 EPS reported -$2.06 revenue$7,473,000

Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.
Operating loss reduced 57% YoY; eight straight quarters of YoY expense cuts.
Cash $6.9M; stockholders' equity $6.3M; expects positive cash flow in early 2025.
Received Medicare reimbursement for CARE oral devices; closed $7.5M equity investment from New Seneca Partners.
New strategic alliance with sleep testing centers in Colorado; pilot showed 79% of patients chose Vivos therapy over CPAP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.